Pipeline — registered trials by phase
inVENT-In-Office Study
— · Otitis Media · Completed · est. 2012-05
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
— · Supratentorial Hemorrhage · Recruiting · est. 2028-10-15
Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX
— · Hip Fracture · Completed · est. 2010-12
CERTAS Programmable Valve Registry
— · Hydrocephalus, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension · Completed · est. 2021-11-18
inVENT-visIOn Study
— · Otitis Media · Completed · est. 2012-05
Bactiseal Catheter Safety Registry Study
— · Hydrocephalus · Recruiting · est. 2026-07-31
HINTEGRA Total Ankle Prosthesis Follow-up
— · Total Ankle Prosthesis · Completed · est. 2010-12
Evaluation of Integra® Artificial Dermis for the Treatment of Leg Ulcers
— · Lower Limb Ulcer · Completed · est. 2015-08
Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy
— · Fibroid, Myoma, Leiomyoma · Completed · est. 2009-05
Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)
— · Recurrent Acute Rhinosinusitis · Completed · est. 2015-10-01
Healthy Volunteer Study
— · Anesthesia of Tympanic Membrane · Completed · est. 2012-02-01
The CUSA Clarity Soft Tissue Removal Study
— · Benign, Malignant Tumors or Other Soft Tissue Removal, Nephrectomy or Partial Nephrectomy With Parenchyma Removal · Completed · est. 2021-11-24
T-GENVIH-003 LTFU (Long Term Follow Up) Study
— · Hernia, Hernia, Ventral, Pathological Conditions, Anatomical · Completed · est. 2024-01-19
Short Term Follow-up of Patient Implanted With the Proximal Interphalangeal Implant
— · Hammer Toe, Claw Toe, Shortening 2nd Toe · Completed · est. 2012-05
A Multicenter, Prospective, Observational Study With PriMatrix for the Treatment of Neuropathic Diabetic Foot Ulcers
— · Foot Ulcers, Diabetic · Completed · est. 2012-09
Earset Healthy Volunteer Study
— · Otitis Media · Completed · est. 2012-08-01
Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide
— · Sinusitis · Completed · est. 2011-11
Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus
— · Acute Otitis Media, Chronic Otitis Media, Recurrent Acute Otitis Media · Completed · est. 2011-01
Balloon Sinus Dilation In Office or OR
— · Chronic Sinusitis · Completed · est. 2009-06-01
External Ventricular Drainage Post-Market Clinical Follow-up Registry
— · Cerebrospinal; Disorder · Completed · est. 2024-12-16
Retrospective Study Evaluating Outcomes for Integra® Skin Sheet Products in Lower Extremity Complex Wounds
— · Complex Lower Extremity Soft Tissue Reconstruction · Completed · est. 2014-09
Large Abdominal Hernia Repair With SurgiMend 3.0
— · Hernia · Completed · est. 2014-07
A Study on the Safety of Hakim Programmable Shunt System
— · Hydrocephalus · Completed · est. 2020-07-28
Short Term Follow-up of Patent Implanted With the B-BOP Lock Plate
— · Hallux Valgus, Hallux Varus, Vicious Callus on M1 · Completed · est. 2012-09
Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis
— · Chronic Sinusitis · Completed · est. 2009-07-01
No registered trials in this stage.
No registered trials in this stage.
Evaluation of the Tympanostomy Tube Delivery System
— · Otitis Media With Effusion, Acute Otitis Media · Completed · est. 2010-11
Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)
— · Chronic Sinusitis · Completed · est. 2006-06
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Integra LifeSciences is lead sponsor; 62 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-10-09Current report (material event)
- 8-K2026-10-02Current report (material event)
- 8-K2026-09-08Current report (material event)
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- SCHEDULE 13G2026-07-31SCHEDULE 13G
- 10-Q2026-07-29Quarterly report
- 8-K2026-07-29Current report (material event)
- SD2026-05-29SD
- SCHEDULE 13G2026-05-15SCHEDULE 13G
- S-82026-05-08Employee stock plan
- 8-K2026-05-08Current report (material event)
- 10-Q2026-05-05Quarterly report
- DEFA14A2026-05-05DEFA14A
- 8-K2026-05-05Current report (material event)
- 8-K2026-05-05Current report (material event)
- 8-K2026-04-15Current report (material event)
- DEF 14A2026-04-06Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- S-3ASR2026-02-26S-3ASR
- 10-K2026-02-26Annual report
- 8-K2026-02-26Current report (material event)
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- 8-K2025-12-12Current report (material event)
- SCHEDULE 13G/A2025-11-06SCHEDULE 13G/A
- 10-Q2025-10-30Quarterly report
- 8-K2025-10-30Current report (material event)
- SCHEDULE 13G/A2025-08-05SCHEDULE 13G/A
- S-82025-07-31Employee stock plan
- 10-Q2025-07-31Quarterly report
- 8-K2025-07-31Current report (material event)
- SCHEDULE 13G/A2025-07-17SCHEDULE 13G/A
- SCHEDULE 13G/A2025-07-09SCHEDULE 13G/A
- 8-K2025-06-09Current report (material event)
- SD2025-05-30SD
- SCHEDULE 13G2025-05-14SCHEDULE 13G
- 8-K2025-05-13Current report (material event)
- SCHEDULE 13G2025-05-09SCHEDULE 13G
- 10-Q2025-05-05Quarterly report
- 8-K2025-05-05Current report (material event)
- DEF 14A2025-04-04Proxy statement
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.